Satish Medakkar: The Importance of Early Recognition in Atypical Hemolytic Uremic Syndrome
Satish Medakkar, Head of Advanced Analytics and Data Science at Alexion Pharmaceuticals, Inc., shared Alexion Pharmaceuticals, Inc.‘s post on LinkedIn, adding:
“Atypical hemolytic uremic syndrome (or aHUS), also known as complement-mediated thrombotic microangiopathy (or CM-TMA), is an ultra-rare condition where parts of your immune system mistakenly attack the cells lining your blood vessels.
This results in small blood clots, which can reduce blood flow to your kidneys and other vital organs.
Healthcare providers usually diagnose aHUS when you have three conditions together: Microangiopathic hemolytic anemia, Thrombocytopenia, and acute kidney injury.
This combination of conditions makes aHUS difficult to diagnose because the episodes can be triggered by other health conditions.”
Alexion Pharmaceuticals, Inc. shared a post on LinkedIn:
“Timely and accurate diagnosis is critical for people living with atypical haemolytic uraemic syndrome (aHUS), an ultra-rare, rapidly progressive disease that may result in severe organ damage and death.
aHUS is a type of thrombotic microangiopathy (TMA) that is caused by dysregulation of the complement immune system.
aHUS often presents suddenly and frequently develops into a chronic condition with relapses.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community